Clinical trials: Women With Breast Cancer
Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or…
- Conditions
- Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
- Trial name
- NCT06547840
- Testing
- MOv18 IgE
- Where
- 7 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Epsilogen Ltd
Asymptomatic
Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts
This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts.
- Trial name
- NCT02933489
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Digital Tomosynthesis Mammography, Quality-of-Life Assessment
- Where
- 68 sites in United States, Germany
- Volunteers
- 1,516 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm
GEN1047 for Solid Tumors - First in Human (FIH) Trial
The purpose of this trial is to measure the following in participants with solid tumors who receive GEN1047: The side effects seen with GEN1047 What the body does with GEN1047 once it is administered What GEN1047 does to the body…
- Conditions
- Breast Cancer, Breast Neoplasms, Endometrial Cancer, Endometrial Neoplasm, Ovarian Cancer, Ovarian Neoplasms, Squamous Non Small Cell Lung Cancer (NSCLC-SCC)
- Trial name
- NCT05180474
- Testing
- GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 179 people
- Sponsor
- Genmab
Breast Neoplasms
Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.
To determine the safety and efficacy of LY353381 when compared to tamoxifen in women with advanced or metastatic breast cancer.
- Trial name
- NCT00034125
- Testing
- LY353381, tamoxifen
- Where
- 11 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Breast Neoplasms
In Vitro Study of the Liquid Biopsy Test System of the Diagnostic Value, in Women With Various Forms of Breast Cancer
The Study Objective is to evaluate the diagnostic efficacy of the liquid biopsy system versus the gold standard mammography (or MRI, or Ultrasound) diagnosis in patients with suspected breast cancer.
- Trial name
- ARNABreast (NCT04890340)
- Testing
- ARNA Breast
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- ARNA Genomics US Inc.
Breast Cancer
Dexrazoxane as a Protective Agent in Anthracycline Treated Breast Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy.
- Trial name
- cardioprotec (NCT00955890)
- Testing
- Dexrazoxane hydrochloride
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
This is a phase II, randomized, double-blinded, placebo-controlled trial designed to evaluate the efficacy of fezolinetant (45 mg a day) vs.
- Trial name
- NCT06917313
- Testing
- Fezolinetant
- Where
- 2 sites in United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yale University
Breast Cancer Female, Breast Cancer
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western Pennsylvania
This is a prospective clinical trial that will examine if contrast-enhanced mammography substantially improves breast cancer detection compared to mammography with tomosynthesis, with minimal increase in false-positives, in women…
- Conditions
- Breast Cancer Female, Breast Cancer, Breast Neoplasms, Neoplasms
- Trial name
- TOCEM (NCT04085510)
- Testing
- Contrast-enhanced mammogram
- Where
- 3 sites in United States
- Volunteers
- 1,647 people, healthy volunteers welcome
- Sponsor
- Wendie Berg
Breast Cancer
Improving Surgical Decision-making in Young Women With Breast Cancer
The overall goal of this study is to qualitatively assess the surgical decision-making process from both the patient and physician perspective 1. Conduct short in-person interviews with young women prior to surgery 2.
- Trial name
- NCT02644382
- Testing
- qualitative data collection, survey, decision aid
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery
RATIONALE: Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying how well metformin hydrochloride works in treating women with…
- Trial name
- NCT00984490
- Testing
- metformin hydrochloride, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
ER+ HER2- Advanced Breast Cancer
AZD9496 First Time in Patients Ascending Dose Study
This is a phase 1 open label multicentre study of AZD9496 administered orally in patients with advanced ER+ HER2 negative breast cancer.
- Trial name
- NCT02248090
- Testing
- AZD9496
- Where
- 6 sites in United States, South Korea and 1 more
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Breast Cancer
Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity
This prospective randomized controlled study is conducted to analyze the effect of Goserelin on ovarian function in women with breast cancer in China.
- Trial name
- NCT02518191
- Testing
- GnRHa
- Where
- 2 sites in China
- Volunteers
- 345 people
- Sponsor
- Xiangyun Zong
Breast Cancer, Breast Cancer Female
Microbiome and Association With Implant Infections
The most common tissue expander-related infections are from Staphylococcus and Pseudomonas species. In addition, from breast tissue microbiome studies, Staphylococcus and Pseudomonas show variable abundance across samples.
- Conditions
- Breast Cancer, Breast Cancer Female, Genetic Predisposition to Disease
- Trial name
- NCT05020574
- Testing
- Cephalexin
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Breast Neoplasms
Multimodal Respiratory Physiotherapy in Women Receiving Radiotherapy for Breast Cancer (RESPIRA-BC)
Radiotherapy is an important treatment for breast cancer, but it may affect lung function and physical ability, making everyday activities more difficult.
- Trial name
- RESPIRA-BC (NCT07884968)
- Testing
- Incentive Spirometry (IS) and Positive Expiratory Pressure (PEP) Training, Individualised Exercise Programme (Aerobic and Resistance Training), Patient Education Programme
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- University of Alcala
Breast Cancer, Fatigue
Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer
RATIONALE: Yoga may improve symptoms and quality of life and reduce stress in patients with ovarian cancer or breast cancer and may help them live more comfortably.
- Conditions
- Breast Cancer, Fatigue, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00337233
- Testing
- yoga therapy
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Wake Forest University Health Sciences
Estrogen Receptor Positive Breast Cancer
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer
This is a two stage study, with an initial dose escalation phase I study and subsequent double blind randomised phase II controlled trial.
- Trial name
- FAKTION (NCT01992952)
- Testing
- AZD5363, Fulvestrant
- Where
- 21 sites in United Kingdom
- Volunteers
- 149 people
- Sponsor
- Velindre NHS Trust
Colorectal Cancer (CRC), Endometrial Cancer
Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors
This is an open-label, multicenter, Phase 1b platform study in subjects with advanced or metastatic solid tumors (Part 1a) and subjects with selected solid tumors (Part 1b and Part 2).
- Conditions
- Colorectal Cancer (CRC), Endometrial Cancer, Melanoma, Head and Neck Cancer
- Trial name
- NCT02646748
- Testing
- Pembrolizumab, itacitinib, INCB050465
- Where
- 17 sites in United States
- Volunteers
- 159 people
- Sponsor
- Incyte Corporation
Ovarian, Breast
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and…
- Conditions
- Ovarian, Breast, SCLC, Gastric Cancers
- Trial name
- MEDIOLA (NCT02734004)
- Testing
- Olaparib, MEDI4736, Bevacizumab
- Where
- 47 sites in United States, France and 5 more
- Volunteers
- 264 people
- Sponsor
- AstraZeneca
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine ditartrate, work in different ways to stop the growth of tumor…
- Conditions
- Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma
- Trial name
- NCT01155258
- Testing
- temsirolimus, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Southern California
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.